TX、GX和NX方案治疗蒽环类耐药晚期三阴性乳腺癌的疗效及安全性

摘要

目的:观察卡培他滨联合多西他赛(TX)或吉西他滨(GX)或长春瑞滨(NX)治疗蒽环类耐药晚期三阴性乳腺癌的疗效及安全性.方法:选择自2014年7月至2015年7月临床应用含卡培他滨方案联合化疗的共98例晚期三阴性乳腺癌患者作为研究对象,其中TX方案组34例,GX方案组34例,NX方案组30例.每2周期评价1次疗效,观察并比较三组患者的近期疗效、疾病进展时间和不良反应.结果:每例患者均接受4～8周期化疗,全组患者共接受581次化疗.TX方案CBR为79.4%,中位TTP 9.1个月;GX方案CBR为73.5%,中位TTP 8.7个月;NX方案CBR为73.3%,中位TTP 8.5个月.主要不良反应均可耐受.结论:对于蒽环类耐药晚期三阴性乳腺癌,以卡培他滨为基础的联合化疗可提高疾病缓解率、延长疾病进展时间,患者耐受性好,是不能耐受两药或三药联合静脉化疗患者的较好选择.%Objective:To investigate the efficacy and safety of capecitabine plus docetaxel (TX)or gemcitabine (GX)or vinorelbine(NX)chemotherapy in patients with anthracycline-resistant metastatic triple-negative breast cancer(mTNBC).Methods:98 mTNBC patients treated with capecitabine-based combination chemotherapy between July 2014 and July 2015 were retrospectively analyzed,TX group of 34 patients,GX group of 34 patients,while NX group of 30 patients.The clinical response was evaluated every two cycles,we observed and compared the therapeutic efficacy,the time to progression(TTP)and safety of the three groups.Results:98 patients received a range of 4～8 cycles of a capecitabine maintenance therapy,overall 581 cycles.In group of TX,the CBR was 79.4%,and the medi-an TTP was 9.1 months.For the group of GX,the CBR was 73.5%,the median TTP was 8.7 months.For NX,the CBR was 73.3%,the median TTP was 8.5 months.The major toxicities were tolerable.Conclusion:Capecitabine-based combination therapy can prolong time to progression and improve the disease remission rate of patients with a favorable safety profile in anthracycline-resistant TNBC patients,it＇s a better selection for the intolerant patients with multidrug combined venous chemotherapy.